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Abstract
Background: Specific IgE (sIgE) is often used to predict oral food challenge
(OFC) outcomes in food allergy, but interpretation of the results may vary
depending on the assay method employed and the patient population tested. The
aim of this study was to use two commercial assay systems to determine egg-sIgE
values predictive of allergy within the most common populations treated at pedi-
atric clinics.
Methods: In a multicenter prospective study, 433 children with suspected or con-
firmed egg allergy underwent oral challenge (OFC) using cooked egg (CE) and
raw egg (RE) powders to diagnose either true allergy in 1-year-old (group A,
n = 220) or tolerance in 2- to 6-year-old (group B, n = 213). Egg white (EW)-
and ovomucoid (OM)-sIgE values were measured using the ImmunoCAP sIgE
(ImmunoCAP) and the IMMULITE 2000 3 gAllergyTM (3gAllergy) systems.
Children were recruited from six primary care clinics and 18 hospitals in Japan.
Results: Receiver-operating characteristic (ROC) curve analysis yielded similar
areas under the curve (AUC) for the two assays (0.7–0.8). The optimal cutoff val-
ues and the probability curves (PCs) of the sIgE by the two assays to predict CE
and RE OFC outcomes were determined for both groups. Values for 3gAllergy
were higher than for ImmunoCAP; however, correlation of sIgE and predicted
probability calculated by PCs were strong between the two methods.
Conclusions: Cutoff values and PCs for egg-sIgE established using both Immuno-
CAP and 3gAllergy may be useful for predicting egg allergy in early childhood
patient populations.
Recent advances in specific IgE (sIgE) assay technology (1)
has enabled quantitative interpretation of serum IgE levels of
defined allergen specificity instead of dichotomous (qualita-
tive) results determined following allergen exposure. Quantifi-
cation is especially helpful for diagnosis, and also for
monitoring young children during ongoing care to determine
whether food allergy persists or whether it has been out-
grown (2, 3). However, present assays do not quantitate the
physiological sIgE titer, but only measure relative abundance
of sIgE bound to an allergen immobilized on a solid surface.
Binding is dependent on the assay’s allergen extract source
and physical properties of the immobilized allergen that
affect epitope conformation. Thus, results expressed as units
do not generate the same value using different manufac-
turer’s methods, leading to the occurrence of considerable
discrepancy (4–6). Because of this, it is important that physi-
cians interpreting the results understand the predictive sIgE
levels of the particular assay they use. Several studies have
reported the predictive sIgE values for a variety of food aller-
gens (7–13) but mostly using only one assay system: Immu-
noCAP specific IgE (ImmunoCAP; Phadia, Thermo Fisher
Scientific, Inc., Uppsala, Sweden). Similar data are essential
for meaningful use of the IMMULITE 2000 3gAllergyTM
system (3gAllergy; Siemens Healthcare Diagnostic Inc., Tar-
rytown, NY, USA), a popular, widely used sIgE assay system
with an extended measurement range.
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Allergy
Although oral food challenge (OFC) is the gold standard
for the diagnosis of food allergy, it is inherently accompanied
by the risk of inducing severe symptoms, including anaphy-
laxis (14). It is also considerably time-consuming, and these
factors can hinder its application at primary care clinics
where a large number of children with suspected food allergy
typically present. To avoid unnecessary OFC, the use of 90
or 95% positive decision points has been proposed. These
points are based on probability curves determined using
quantitative sIgE measurement (7, 12, 13, 15–17) and may be
used in various clinical settings. However, these statistically
calculated predictive values can vary significantly among clin-
ics or institutions depending on the assay used and character-
istics of the study population, such as age, severity, and
prevalence of positive reactions. The treatment of the food
used in OFC, that is, raw, cooked, or baked, is also impor-
tant. Thus, predictive values estimated at a single center (as
calculated in most of the previous reports) may not be appli-
cable to patients at other clinics. Discrepancies have been
noted among retrospective studies, and such study designs
also pose significant risk of bias. Thus to provide reliable
and applicable values to clinicians, prospective, multicenter
studies are needed using populations representative of those
commonly seen by clinicians in daily clinical settings.
Egg is one of the most common causes of food allergy in
young children, but rare in adults as most individuals out-
grow egg allergy during childhood (18, 19). Because of its
high prevalence and changing allergic status in very young
children, demand is high for correct and early diagnosis of
egg allergy. Two populations are seen most commonly in
daily clinics. The first population comprises children with
infantile atopic dermatitis who are suspected early of food
sensitization, and upon recommendation of the pediatrician
have not consumed eggs during the first year of life, and now
require sIgE testing to confirm allergy (20). The second pop-
ulation is composed of preschool children practicing egg
avoidance due to confirmed egg allergy, and who require test-
ing to determine whether the allergy has been outgrown. In
our multicenter Improvement of Proper Allergy Diagnostics
utilizing 3gAllergy study (IPAD3g) conducted at primary
care clinics, general pediatric hospitals, and pediatric allergy-
specialized hospitals, we prospectively analyzed the relation-
ships between egg OFC outcomes and sIgE values using the




Young children aged 1–6 years who had hen’s egg OFC at
six private practice clinics and 18 hospitals (six pediatric
allergy-specialized hospitals and 12 general pediatric hospi-
tals) in Japan were enrolled in the multicenter study from
August 2012 to August 2014. All the patients were consum-
ing an egg-free diet prior to the OFC because of suspected or
diagnosed egg allergy and had no apparent history of egg-
induced symptoms or had not undergone egg OFC within
3 months before the study OFC. OFC was performed at the
time of the study as a requisite diagnostic procedure. Before
the OFC, the patients were invited to join the study to test
validity and performance of the two sIgE assays (Immuno-
CAP and 3gAllergy). The study was reviewed and approved
by the Institutional Review Board of Mie National Hospital
(principal investigator site). Written informed consent from
parents and informed assent from children older than 3 years
were obtained before enrollment.
Eligible subjects (n = 433) were divided into two study
groups. Group A (n = 220) consisted of 1-year-old children
who had either never eaten egg but who had been tested for
egg sensitization during infancy because of infantile eczema/
atopic dermatitis, (20) or who had eliminated egg for more
than 6 months due to mild egg-induced symptoms and egg
sensitization. Group B (n = 213) consisted of 2- to 6-year-old
children who had eliminated egg for more than 12 months
because of a diagnosed egg allergy, confirmed by OFC or
apparent egg-induced history with documented egg sensitiza-
tion, or who had never eaten egg because of egg sensitization.
Sensitization to egg was defined as EW-sIgE >0.1 either by
ImmunoCAP (kUA/L) or 3gAllergy (IUA/mL). Patients were
excluded if they had:
• apparent symptoms after ingestion of egg within
3 months before the OFC,
• egg OFC within 3 months before the current OFC,
• uncontrolled atopic dermatitis/asthma,
• other chronic diseases.
Group A patients were investigated for the determination
of ‘true’ egg allergy, and group B patients were tested to
determine whether or not they had ‘outgrown’ their previ-
ously diagnosed egg allergy.
Oral food challenges
Every subject underwent a single-blind OFC using cooked
egg (CE) powder (Kewpie Corporation, Tokyo, Japan). Pow-
der was produced by boiling hen’s egg at 95°C for 15 min,
followed by pasteurization at 65°C for 20 min, and then
spray-dried. Raw egg (RE) was used to create RE powder by
spray-drying followed by pasteurization at 75°C for 4 days in
a preservation room. One egg equivalent for both powders
was 13 g. Pumpkin, sweet potato or cocoa powders were
used to mask color and taste of egg. The total dose of CE
powder used in each challenge was 6.5 g for group A (1/2
egg) and 13 g for group B (one egg). The dose of RE powder
was 4 g (1/4 egg) for both groups. The challenge food was
divided into six graded doses (2/100, 4/100, 8/100, 16/100,
32/100 and 38/100), and each increased dose was adminis-
tered at 15- to 30-min intervals. The OFC was considered
positive if objective clinical reactions were noted, such as
urticaria, angioedema, rhinoconjunctivitis, cough, wheezing,
vomiting, diarrhea, or a decrease in blood pressure. Intense
abdominal pain (self-rated as 1 or 2 using a 5-graded pain
intensity face scale) was also considered positive even if other
objective signs were not observed. OFC was considered nega-
tive if no symptoms were observed for 2 h after ingesting the
total amount of the powder at a challenge. Full emergency
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equipment and medications were readily available during the
course of all procedures. Antihistamine was suspended 72 h
before the OFC.
Specific IgE measurements
Serum samples from all subjects were collected on the day of
OFC or within 4 weeks before OFC. sIgE to egg white (EW)
and ovomucoid (OM) were determined using ImmunoCAP
and 3gAllergy. The ImmunoCAP reports quantitative results
in kilo-units of antibody per liter (kUA/L); according to the
manufacturer, the lower detection limit (LoD) is 0.1 kUA/L
and the upper limit is 100 kUA/L. The 3gAllergy assay
reports results in international units of antibody per liter
(IUA/mL), and as per the manufacturer, LoD = 0.1 IUA/mL
and the upper limit = 500 IUA/mL.
Statistical analysis
All data were analyzed according to the intention-to-treat
principle. For the baseline variables, summary statistics were
constructed employing frequencies and proportions for cate-
gorical data, and means and standard deviations (SD) for
continuous variables. Predictive accuracy of sIgE for OFC
outcome was assessed by receiver-operating characteristic
(ROC) analysis to determine the area under the curve
(AUC). The AUC was estimated using a form of the trape-
zoid method, and the 95% confidence interval (CI) for the
AUC was estimated by the Wald test statistic (21). The opti-
mal cutoff point was determined to maximize the Youden
index (sensitivity + specificity – 1). Sensitivity, specificity, pos-
itive predictive values (PPV) and negative predictive values
(NPV), and positive and negative likelihood ratios (LR+ and
LR-) were then calculated for the cutoff. Probability of a
positive OFC outcome for both cooked and raw eggs was
estimated using logistic regression according to the method
of S€oderstr€om et al., (22) and used to generate probability
curves with 95% CIs for EW-sIgE and OM-sIgE for each
patient group, on each system. The factors associated with
OFC outcomes were also investigated by a stepwise selection
procedure in a multivariate logistic regression model. A non-
parametric test (Mann–Whitney U-test) was used to compare
OFC-positive and OFC-negative groups;
P < 0.05 was considered statistically significant. All statisti-
cal analyses were planned and performed using the SAS soft-
ware program, version 9.4 (SAS Institute, Cary, NC, USA).
Results
Demographics of the patients
Patient demographics are summarized in Table 1. There
were more boys, 64%, than girls. Median ages were 16 and
48 months in groups A and B, respectively. History of egg-
induced symptoms was present in 27.3% of group A and
58.7% of group B. Most of the subjects had history of
eczema in infancy, which prompted the attending physicians
to test egg sensitization of the patients. Comorbid atopic
dermatitis was observed in 72.1% and majority of them
were controlled and mild in severity. Asthma was found in
22.4%.
OFC outcomes
Of the 433 patients who underwent CE OFC, 243 patients
passed (negative OFC) and 190 failed (positive OFC).
Among the patients who passed the initial OFC, 130 patients
declined to have RE OFC, while 113 underwent the second
OFC: 55 passed and 58 failed. As the patients who failed CE
OFC are unlikely to pass RE OFC because of the high
Table 1 Demographics of the study population who had cooked hen’s egg oral food challenge
Characteristics
Group A: 12 – 23
months old (n = 220)
Group B: 24 – 83
months old (n = 213) Total (n = 433)
Gender M/total (male%) 141/220 (64.1) 136/213 (63.8) 277/433 (64.0)
Age (months) Median (range) 16 (12–23) 48 (24–83) 23 (12–83)
OFC performed at:
Hospital N (%) 115/220 (52.3) 154/213 (72.3) 269/433 (62.1)
Clinic N (%) 105/220 (47.7) 59/213 (27.7) 164/433 (37.9)
Egg allergy suspected because of:
Sensitization to hen’s egg* N (%) 220/220 (100) 213/213 (100) 433/433 (100)
History of egg-induced symptoms† N (%) 60/220 (27.3) 125/213 (58.7) 185/433 (42.7)
Previous OFC† N (%) 2/220 (0.9) 36/213 (16.9) 38/433 (8.8)
History of eczema in infancy N (%) 182/216 (84.3) 159/208 (76.4) 341/424 (80.4)
Diagnosis of atopic dermatitis N (%) 165/210 (78.6) 137/209 (65.6) 302/419 (72.1)
Severity of atopic dermatitis
Mild N (%) 155/210 (73.8) 111/209 (53.1) 266/419 (63.5)
Moderate N (%) 9/210 (4.3) 24/209 (11.5) 33/419 (7.9)
Severe N (%) 1/210 (0.5) 2/209 (1.0) 3/419 (0.7)
Diagnosis of asthma N (%) 27/214 (12.6) 68/210 (32.4) 95/424 (22.4)
*Hen’s egg white-specific IgE ≥0.1 (ImmunoCAP or 3gAllergy).
†The present OFCs were performed more than 6 months after a recent history of induced symptoms and previous OFC.
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allergenicity of raw egg (23), they were included in the analy-
sis for RE OFC as positive (Fig. 1). Symptoms induced by
OFCs were predominantly cutaneous, such as urticaria and
itchy erythema. Gastrointestinal and respiratory symptoms
such as abdominal pain, vomiting, cough, and wheeze
appeared in about 30% of the subjects (Table S1). Epinephr-
ine injections were required during the CE OFC for 17
patients (3.9%), and during RE OFC for four patients
(3.5%); all the subjects recovered promptly without sequelae.
There were no cardiovascular symptoms (Table S1).
Diagnostic performance of sIgE assays by ImmunoCAP and
3gAllergy
EW-sIgE and OM-sIgE by ImmunoCAP and 3gAllergy in
patients who failed corresponding OFCs were significantly
433 patients underwent CE OFC
Group A: 220
Group B: 213
113 patients underwent RE OFC
Group A: 65
Group B: 48
Passed (n = 243)
Group A: 139
Group B: 104
Passed (n = 55)
Group A: 28
Group B: 27
Failed (n = 58)
Group A: 37
Group B: 21
Declined (n = 130)
Group A: 74
Group B: 56
Failed (n = 190)
Group A: 81
Group B: 109
Figure 1 OFC flow diagram showing a cascade of ‘Passed’ (negative OFC) and ‘Failed’ (positive OFC) outcomes.
Table 2 Diagnostic performance of sIgE assays in predicting OFC outcomes






(%) PPV (%) NPV (%) LR+ LR
(a) CE performance
Group A EW ImmunoCAP 0.671 0.599–0.744 7.4 75.3 56.1 50.0 79.6 1.72 0.44
EW 3gAllergy 0.690 0.618–0.762 54.2 61.7 72.7 56.8 76.5 2.26 0.53
OM ImmunoCAP 0.778 0.712–0.843 3.1 72.8 77.7 65.6 83.1 3.27 0.35
OM 3gAllergy 0.791 0.726–0.856 21.5 66.7 85.6 73.0 81.5 4.63 0.39
Group B EW ImmunoCAP 0.786 0.724–0.847 9.1 78.0 67.3 71.4 74.5 2.39 0.33
EW 3gAllergy 0.797 0.737–0.856 28.5 85.3 62.5 70.5 80.2 2.28 0.23
OM ImmunoCAP 0.828 0.773–0.883 9.0 66.1 89.4 86.7 71.5 6.25 0.38
OM 3gAllergy 0.848 0.796–0.899 45.4 65.1 92.3 89.9 71.6 8.47 0.38
(b) RE performance
Group A EW ImmunoCAP 0.671 0.534–0.808 3.7 75.7 60.7 71.8 65.4 1.93 0.40
EW 3gAllergy 0.678 0.542–0.814 15.4 73.0 60.7 71.1 63.0 1.86 0.45
OM ImmunoCAP 0.574 0.432–0.717 0.5 54.1 67.9 69.0 52.8 1.68 0.68
OM 3gAllergy 0.634 0.492–0.776 3.0 56.8 71.4 72.4 55.6 1.99 0.61
Group B EW ImmunoCAP 0.742 0.632–0.852 3.0 84.7 60.7 90.1 48.6 2.16 0.25
EW 3gAllergy 0.762 0.660–0.865 22.9 74.6 71.4 91.7 40.0 2.61 0.36
OM ImmunoCAP 0.734 0.629–0.839 0.6 72.0 71.4 91.4 37.7 2.52 0.39
OM 3gAllergy 0.766 0.663–0.869 3.0 78.8 71.4 92.1 44.4 2.76 0.30
AUC, area under the curve; PPV, positive predictive value; NPV, negative predictive value; LR+, positive likelihood ratio; LR–, negative likeli-
hood ratio.
*Units are kUA/L for ImmunoCAP and IUA/mL for 3gAllergy.
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higher than those who passed (Table S2). Predictive accuracy
of the two sIgE tests for OFC outcomes was evaluated using
ROC analysis. Overall, the AUCs were higher in group B than
in group A, indicating that in vitro sIgE predictive ability is
lower when conducted at a younger age (Tables 2a and 2b). In
terms of the test methods employed, ImmunoCAP and 3gAl-
lergy showed equivalent accuracy in respective OFCs based on
the AUC. Optimal cutoff points were higher with 3gAllergy
than ImmunoCAP. In CE OFC, the AUC for OM-sIgE was
higher than for EW-sIgE, as has been shown previously
(Table 2a) (24). Conversely, in RE OFCs, EW-sIgE AUCs
were slightly higher than AUCs for OM-sIgE (Table 2a).
LR+s for OM-sIgE in CE OFC were satisfactorily high for
both ImmunoCAP (6.25) and 3gAllergy (8.47, Table 2b).
Predictive probability for positive OFC
The relationships between OFC outcomes and sIgE levels by
ImmunoCAP and 3gAllergy were estimated using logis-
tic regression and illustrated as probability curves (Figs 2
and 3). The curves clearly demonstrate risk of a positive
OFC dependent on the sIgE level. To determine the utility in
clinical decision-making, EW- and OM-sIgE levels were cal-
culated for each of the two methods at 90%, 80%, and 10%
predicted probability for a positive OFC (Table 3). Overall,
slopes of the probability curves were more gradual and their
95% CIs were broader for group A than group B, suggesting
that diagnostic performance of these tests is not as good for
children <2 yrs as it is for older children. However, consider-
ing that the predefined total challenge dose in CE OFC for
group A was half of a whole egg equivalent, whereas the
dose for group B was one whole egg equivalent, the lower
predicted probability at higher sIgE levels in group A indi-
cates that 1-year-old infants in this study population are
more likely to tolerate egg in small amounts than their older
counterparts (Fig. 2).
A multivariate logistic regression analysis was applied to
specify a factor that independently affects OFC outcomes.
OFC outcome was applied as the response variable; age, gen-
der, comorbid atopic dermatitis and asthma/wheezing, and
A B
C D
Figure 2 Predicted probability derived from logistic regression for
CE OFC outcomes. Estimated probability curves for failing CE OFC
at a given EW-sIgE level by ImmunoCAP (A) and 3gAllergy (B),
OM-sIgE level by ImmunoCAP (C) and 3gAllergy (D) are depicted.
Shaded areas indicate range of 95% CI. Blue lines and shades
indicate group A and red lines and shades indicate group B.
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EW- or OM-sIgE by one of the two assays were applied as
the explanation variables. None of the factors were indepen-
dently associated with OFC response except for each of the
sIgE outcomes (data not shown).
Correlation of the two sIgE tests
As the probability curves for ImmunoCAP and 3gAllergy
were very similar in shape (Figs 2 and 3), we looked at the
correlation between EW- and OM-sIgE values by the two
assays and found that they were strongly correlated; Pear-
son’s correlation coefficient was 0.97 for EW and 0.95 for
OM (Fig. S1). We also examined correlation between each
predicted probability by ImmunoCAP and 3gAllergy for
individual patients and found that probability of response
was also strongly correlated between the two systems
(R = 0.98 for EW and 0.93 for OM, Fig. S2). Because log-
transformed data of the sIgE values by ImmunoCAP and
3gAllergy showed linear correlation, equations for transfor-
mation could be established and a conversion table was also
constructed (Table S3).
Discussion
In this prospective multicenter study, we identified predictive
values for OFC outcome in young children with suspected
egg allergy for EW- and OM-sIgE measured by two com-
monly used quantitative sIgE assay systems (ImmunoCAP
and 3gAllergy). Predictive values like 95% positive decision
points and probability curves are highly dependent on char-
acteristics of a study population, such as prevalence of posi-
tive outcome, severity of the disease and the presence of
comorbid diseases. For this reason, we recruited subjects
from a variety of primary care and specialized clinics. The
majority of patients are very likely to be examined at daily
clinics, where a physician has to ponder whether or not a
toddler has a ‘true’ egg allergy, and likewise, whether or not
a preschool-aged child has ‘outgrown’ egg allergy. The pre-
dictive values that we have established in this study fit these
clinical needs.
Allergenicity of the food used in an OFC must also be
considered when interpreting the results to apply them cor-
rectly to the daily diet recommended to food-allergic patients.
A B
C D
Figure 3 Predicted probability derived from logistic regression for
RE OFC outcomes. Estimated probability curves for failing CE OFC
at a given EW-sIgE level by ImmunoCAP (A) and 3gAllergy (B),
OM-sIgE level by ImmunoCAP (C) and 3gAllergy (D) are depicted.
Shaded areas indicate range of 95% CI. Blue lines and shades indi-
cate group A, and red lines and shades indicate group B.
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Allergic potency of egg in particular vastly changes by cook-
ing or processing because heating reduces or denatures aller-
gen epitopes (25). For this reason, we estimated the ability of
EW- and OM-sIgEs to predict a positive response when a
patient is exposed to either cooked or raw egg in an OFC.
Another important aspect of this study was our identifica-
tion of EW- and OM-sIgE titers predictive of egg allergy in
young children using 3gAllergy. This is the first study to
determine these values using this system, which is a quantita-
tive sIgE assay with an extended measurement range. Until
now, the predictive values of sIgE in food allergy have been
determined mostly using the ImmunoCAP system, making
interpretation of the values measured by other assays diffi-
cult. Some reports argue that 3gAllergy overestimates IgE
values (4, 6) However, assays from different vendors com-
monly produce disparate values, and in any assay compar-
ison, it is expected that there will be differences between the
reference assay and the comparison assay. In one study, for
example, 3gAllergy appeared to underperform ImmunoCAP
(4). However, at least one study has shown that in terms of
assay performance – including accuracy and reproducibility –
the 3gAllergy system appears to be comparable to the
ImmunoCAP system (1). 3gAllergy utilizes a solid-phased liq-
uid-phase reaction system that might have several potential
advantages; 1) the amount of allergen can be optimized
within the reaction system, 2) the biotinylated allergen epi-
topes within the liquid phase are less likely to be blocked by
the solid phase, possibly resulting in better reaction kinetics
and thermodynamics, and 3) the system exhibits less non-
specific absorption of antibodies (26, 27). Ultimately, the real
question is whether the results of the assay are reliable for
guiding clinical decisions. We have clearly shown in this
study that both commercial assays have comparable perfor-
mance in predicting OFC outcomes in egg allergy, although
3gAllergy has the slightly higher AUCs and LR+s than
ImmunoCAP.
Recently, a systematic review reported on the diagnostic
accuracy of skin prick testing (SPT) vs sIgE in the clinical
diagnosis of food allergy (28). The authors comprehensively
reviewed the risk of bias in the literature and proposed cutoff
values at which SPT and sIgE measured by ImmunoCAP
were diagnostic for EW allergy. In this study, which was con-
ducted using children <2 years of age, allergy to raw egg
seems very likely when, using EW extract, SPT generates
urticaria ≥4 mm, or when sIgEs are ≥1.7 kUA/L. In children
≥2 years, OFC could be avoided when SPT wheals with EW
extract are ≥10 mm, prick by prick wheals are ≥14 mm, or
specific IgE is ≥7.3 kUA/L (28). Compared with these
reported values, cutoffs found in our study were rather high:
for ImmunoCAP, EW-sIgEs ≥18.7 kUA/L and OM-sIgEs
≥5.7 kUA/L were predictive of egg allergy in children
<2 years, while in children ≥2 years, EW-sIgEs ≥11.5 kUA/L
and OM-sIgEs ≥6.1 kUA/L were predictive (Table 3). How-
ever, this discrepancy does not indicate our results are inac-
curate. We used different target doses of the challenge food
in OFC: instead of using one whole egg equivalent of egg as
in the former review, our target dose was set at 1/4 of whole
egg. The OFCs in the former study were designed to test for
complete tolerance to egg, while we aimed for investigating
partial but reasonable tolerance of egg consumption. In real-
ity, children who have outgrown their egg allergy do so in a
gradual and continuous manner. During this process, a child
in the progression of outgrowing egg allergy might not be
able to tolerate the amount of protein found in a whole egg,
but it can be beneficial for the child if small amounts of CE
can be consumed. Because the criteria for a positive OFC
were broad, the sIgE cutoff was higher.
It is notable that sIgE values measured by ImmnoCAP
and 3 gAllergy are strongly correlated. Variability in values
observed using assays from manufacturers might be attribu-
table to the use of different capture antibodies and/or detec-
tion chemistries. This might result in different absolute
values, and the heterogeneity of allergens used in the assays
may also contribute to the disparity in values. Interestingly,
however, we found good agreement between the two assays
not only in the absolute values detected, but also in the
probabilities estimated for OFC outcomes except for small
discrepancy in OM-sIgE at low range (Figs S1 and S2). As
we included the subjects who had documented egg sensitiza-
tion based on positive EW-sIgE, and not on OM-sIgE, neg-
ative OM-sIgE results were more frequently observed with
ImmunoCAP than 3gAllergy, which may indicate the latter
assay is more sensitive than the former in the detection of
OM-sIgE. Nevertheless, the findings have shown strong cor-
relation between the two assays, indicating that both the
ImmunoCAP and 3gAllergy accurately represent the clinical
status of allergy, at least, with respect to egg allergy in
children.
Table 3 Egg-sIgE antibody levels with estimated 90%, 80%, and















EW ImmunoCAP n.e. n.e. 0.2
EW 3gAllergy n.e. n.e. 0.2
OM ImmunoCAP n.e. 71.1 n.e.
OM 3gAllergy n.e. 355.0 0.3
RE
OFC
EW ImmunoCAP 18.7 4.9 n.e.
EW 3gAllergy 63.2 18.9 0.1
OM ImmunoCAP 5.7 0.9 n.e.




EW ImmunoCAP n.e 43.5 0.8
EW 3gAllergy 355.0 150.0 3.3
OM ImmunoCAP 50.0 18.7 0.3
OM 3gAllergy 211.0 81.9 1.8
RE
OFC
EW ImmunoCAP 11.5 5.3 0.2
EW 3gAllergy 37.7 18.9 0.9
OM ImmunoCAP 6.1 2.1 n.e.
OM 3gAllergy 24.5 9.5 0.2
n.e., not estimated.
*KUA/L for ImmunoCAP, IUA/mL for 3gAllergy.
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This study did have a limitation. We did not perform dou-
ble-blind placebo-controlled food challenges (DBPCFC), the
gold standard in the diagnosis of food allergy. The single-
blinded OFC without placebo used in this study may be
prone to bias. However, we considered the OFC to be posi-
tive only when objective clinical reactions were confirmed.
Our intention was to find the predictive values in ‘real-world’
settings where DBPCFC is usually difficult to perform as a
routine diagnostic procedure because of its time-consuming
nature.
In conclusion, we evaluated two commercial in vitro meth-
ods (ImmunoCAP and 3gAllergy) to determine the predictive
values of EW-sIgE and OM-sIgE in young children who
require a confirmed diagnosis of egg allergy/tolerance. The
value estimated to be predictive of OFC response in patients
may be useful as a supportive diagnostic tool in egg allergy.
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